Vialwise
EN

BPC-157 + TB-500

A mix of two separate peptides, BPC-157 and TB-500, sold together in one vial. Neither part is approved as a medicine. No controlled human study has tested the combination; one rat study tested the two together.

Not approved · research onlyWADA Prohibited at all times (BPC-157 under S0, TB-500 under S2)Checked October 2026
Open the BPC-157 + TB-500 calculatorSources

Approval status

Neither part is approved as a medicine in any country. In July 2026 FDA and its advisory panel reviewed each part separately for pharmacy compounding, not the combination. See each part for its status.123

What it’s used or studied for

  • Animal & lab only

    Tendon healing: in a 2026 rat study of repaired Achilles tendons, the two given together did no better than either one alone.4

Each label shows how strong the evidence is: an approved use, human studies, animal or lab studies only, or a popular claim with no published studies. Being studied is not the same as being proven safe or effective.

Side effects

One report to FDA described skin and gum darkening that came back when a person restarted a product containing both BPC-157 and TB-500. FDA could not say which part caused it.5

A blend carries the side effects and cautions of each of its parts.

Sources

  1. FDA briefing document: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (introduction)
  2. AJMC news: FDA panel backs 6 peptides for compounding (July 31, 2026)
  3. World Anti-Doping Agency: 2026 Prohibited List (in force from January 1, 2026)
  4. Biçer et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Jt Dis Relat Surg
  5. FDA briefing document: Evaluation of BPC-157 for the 503A bulks list (PCAC meeting, July 2026)

Spotted a mistake on this page? Report it. The email opens with the peptide and vial already filled in.